2021

Submission to the Pharmac Review

Lung Foundation New Zealand (LFNZ) filed a submission (link below) to the pharmac review committee and participated in the review forum held at the Ministry of Health in Wellington alongside many other patients groups. LFNZ has collaborated with other advocacy groups to provide the review committee with insights into the experiences of patients and too […]

The First Lung Cancer Quality Improvement Report by Te Aho o Te Kahu, Cancer Control Agency

It is acknowledged The Lung Cancer Quality Report aims to provide information to help District Health Boards deliver consistent, high-quality cancer care. We too understand the purpose of the report is to analyse data from District Health Boards (DHBs) against eight quality performance indicators (QPIs) to identify disparities in care and variation in outcomes. Whilst […]

Lung Cancer Research Review

Lung Foundation New Zealand (LFNZ) really values collaborating with Research Review and we too are pleased to promote the latest issue of Lung Cancer Research Review (per link below). LFNZ acknowledge’s the leadership of Dr Paul Dawkins and Dr Aileen Ludlow, together with the team at Research Review, for their expertise and time to prepare […]

World Cancer Day 4th February 2021

World Cancer Day, is the global uniting initiative led by the Union for International Cancer Control (UICC). The 2021 World Cancer Day theme, ‘I Am and I Will’, is all about each person and their personal commitment to reduce the impact of cancer. Lung Foundation New Zealand is proud to be a member of UICC. Click […]

Lung cancer biomarkers inform treatment options

Our view is that patients in NZ should be tested for the following biomarkers at the time of diagnosis (and informed of the results irrespective of the reimbursement status of treatment options); ALK, EGFR, KRAS, RET, MET, ROS1, BRAF, HER2, NTRK1 And PD-L1. We too consider these diagnostic procedures should be part of all DHB’s […]